November saw Celsion shares climb 71%, putting the stock at a year-to-date total of a 360% gain. The company is advancing its ThermoDox process through phase 3 trials for liver cancer. The process uses heat-sensitive nanoparticles that are then heated through RF ablation to kill tumors. More focus will be on this company in the near future as it moves closer to its phase 3 results, but as with any biotech stock with an upcoming binary event that could really drive share prices either way, the risk is inherently high; if the tests are a failure, the sell-off could be enormous.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article November Nearly Doubled This Biotech's Shares originally appeared on Fool.com.David Williamson and Max Macaluso have no positions in the stocks mentioned above. Follow David on Twitter @MotleyDavid. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.